Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience — Sara Guerrieri (2021) | RDL Network
Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience
Article 2021 en
Authors
SG
Sara Guerrieri
SL
Serena Marita Lazzarin
CZ
Chiara Zanetta
Abstract
1 min read
Our initial real-life experience suggests a variable antibody production in MS patients receiving these DMTs. At present, there are no sufficient data to do not recommend anti-SARS-CoV-2 vaccine in these patients.
Efstathios Kastritis, Evangelos Terpos, Aimilia D. Sklirou, Foteini Theodorakakou, Despina Fotiou, Eleni‐Dimitra Papanagnou, Tina Bagratuni, Nikolaos Kanellias, Maria Gavriatopoulou, Ioannis P. Trougakos, Meletios A Dimopoulos
Margherita Rosati, Evangelos Terpos, Mahesh Agarwal, Vangelis Karalis, Jenifer Bear, Robert Burns, Xintao Hu, Demetrios G. Papademetriou, Ioannis Ntanasis‐Stathopoulos, Ioannis P. Trougakos, Meletios A Dimopoulos, George N. Pavlakis, Barbara K. Felber
Evangelos Terpos, Despina Fotiou, Vangelis Karalis, Ioannis Ntanasis‐Stathopoulos, Aimilia D. Sklirou, Maria Gavriatopoulou, Panagiotis Malandrakis, Vassiliki A. Iconomidou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.